centene corp. - CNC
CNC
Close Chg Chg %
38.82 0.03 0.06%
Closed Market
38.85
+0.03 (0.06%)
Volume: 4.80M
Last Updated:
Dec 4, 2025, 3:59 PM EDT
Company Overview: centene corp. - CNC
CNC Key Data
| Open $38.64 | Day Range 38.40 - 39.00 |
| 52 Week Range 25.08 - 66.81 | Market Cap $19.08B |
| Shares Outstanding 491.52M | Public Float 479.02M |
| Beta 0.48 | Rev. Per Employee N/A |
| P/E Ratio N/A | EPS -$10.81 |
| Yield 0.00% | Dividend N/A |
| EX-DIVIDEND DATE | SHORT INTEREST N/A |
| AVERAGE VOLUME 8.58M |
CNC Performance
| 1 Week | -1.25% | ||
| 1 Month | 3.43% | ||
| 3 Months | 34.06% | ||
| 1 Year | -31.55% | ||
| 5 Years | -39.86% |
CNC Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
23
Full Ratings ➔
An error occurred while fetching the data.
An error occurred while fetching the data.
Snapshot
| Average Recommendation | HOLD | Average Target Price | 37.50 | |
| Number of Ratings | 23 | Current Quarters Estimate | -1.193 | |
| FY Report Date | 12 / 2025 | Current Year's Estimate | 1.996 | |
| Last Quarter’s Earnings | 0.50 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | 7.17 | Next Fiscal Year Estimate | 2.935 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 19 | 16 | 20 | 20 |
| Mean Estimate | -1.19 | 2.21 | 2.00 | 2.93 |
| High Estimates | -0.79 | 3.82 | 2.25 | 3.66 |
| Low Estimate | -1.30 | 0.42 | 1.50 | 1.95 |
| Coefficient of Variance | -10.00 | 29.38 | 7.08 | 13.81 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 3 | 3 | 5 |
| OVERWEIGHT | 2 | 2 | 1 |
| HOLD | 16 | 16 | 15 |
| UNDERWEIGHT | 1 | 1 | 1 |
| SELL | 1 | 1 | 0 |
| MEAN | Hold | Hold | Hold |
SEC Filings for Centene Corp. - CNC
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Centene Corp. - CNC
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Oct 3, 2025 | Frederick H. Eppinger Director | 359,753 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Oct 3, 2025 | Christopher J. Coughlin Director | 12,288 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Oct 3, 2025 | Kenneth A. Burdick Director | 338,372 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Oct 3, 2025 | Theodore Rapp Samuels Director | 19,205 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Oct 3, 2025 | Kenneth Yutaka Tanji Director | 5,948 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 21, 2025 | Susan Smith Chief Operating Officer | 119,923 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 21, 2025 | Susan Smith Chief Operating Officer | 59,775 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $58.19 per share | 3,478,307.25 |
| Mar 21, 2025 | Tanya M. McNally Chief People Officer | 60,458 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 21, 2025 | Tanya M. McNally Chief People Officer | 27,377 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $58.19 per share | 1,593,067.63 |
| Mar 21, 2025 | Katie N. Casso Corporate Controller & CAO | 98,412 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 21, 2025 | Katie N. Casso Corporate Controller & CAO | 70,916 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $58.19 per share | 4,126,602.04 |
| Mar 21, 2025 | Christopher A. Koster Secretary & General Counsel | 261,707 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 21, 2025 | Christopher A. Koster Secretary & General Counsel | 175,782 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $58.19 per share | 10,228,754.58 |
| Mar 21, 2025 | Sarah McGinty London Chief Executive Officer; Director | 826,045 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 21, 2025 | Sarah McGinty London Chief Executive Officer; Director | 564,832 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $58.19 per share | 32,867,574.08 |
| Mar 21, 2025 | Andrew Lynn Asher Chief Financial Officer | 668,208 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 21, 2025 | Andrew Lynn Asher Chief Financial Officer | 444,802 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $58.19 per share | 25,883,028.38 |
| Jan 6, 2025 | Wayne S. DeVeydt Director | 14,801 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
Centene Corp. in the News
Centene cancels in-person investor day after UnitedHealthcare CEO killing, will hold event virtually
Managed health care company Centene announced that it canceled its in-person investor day and moved to a webinar format following the killing of UnitedHealthcare CEO Brian Thompson.
Companies thought they had a plan for fall, now they are scrapping it
The swift, startling resurgence of Covid-19 cases and hospitalizations across the U.S. is causing corporate leaders to rip up playbooks for the next few months.